ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis
- 27 August 2026
- journal article
- review article
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 610
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Precision medicine in bladder cancer: Redefining treatment paradigms through ADCs, immunotherapy, and molecular subtypingCritical Reviews in Oncology/Hematology, 2026
- 3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274Annals of Oncology, 2025
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 GuidelinesEuropean Urology, 2025
- Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancerCancer Cell, 2024
- A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial designEuropean Journal of Cancer, 2024
- Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysisEBioMedicine, 2024
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 GuidelinesEuropean Urology, 2023
- Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaEuropean Urology, 2023
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Genomic Characterization of Upper Tract Urothelial CarcinomaEuropean Urology, 2015